- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03462927
A Maximal Use Trial Evaluating the Pharmacokinetic Profile of MC2-01 Cream
December 9, 2019 updated by: MC2 Therapeutics
A Randomised, Open-label, Maximal Use Trial, Evaluating the Pharmacokinetic Profile of Active Ingredients and Their Metabolites After Application of MC2-01 Cream Compared With Active Comparator in Subjects With Extensive Psoriasis Vulgaris
This is a phase 2, randomised, open-label, parallel-group, multicentre trial in which MC2-01 cream and calcipotriene [CAL]/betamethasone [BDP] ointment (comparator) is investigated in subjects with clinically diagnosed extensive psoriasis vulgaris.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
The MC2-01 cream is designed for optimal patient satisfaction - it quickly absorbs into the skin leaving it nicely moisturized allowing patients to move on with daily routines.
In this trial, the MC2-01 cream will be compared to a marketed calcipotriene [CAL]/betamethasone dipropionate [BDP] ointment.
The purpose of the trial, is to determine the pharmacokinetic parameters of MC2-01 cream and the comparator under maximum use conditions.
Study Type
Interventional
Enrollment (Actual)
63
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Florida
-
Sweetwater, Florida, United States, 33172
- Lenus Research and Medical Group
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Have provided written informed consent.
- Generally healthy males or non-pregnant females, of any race or ethnicity, who are at least 18 years of age at the time of screening.
- At Visit 1/Day 0, have a clinical diagnosis of plaque psoriasis (psoriasis vulgaris) of at least 6 months duration involving scalp and body (trunk and/or limbs) that is amenable to topical treatment with a maximum of 100 g of trial medication per week.
- Have a Physician's Global Assessment [PGA] of severity of at least moderate on the trunk, limbs and/or scalp, at Visit 1/Day 0.
- Have a treatment area between 20% and 30% of the body surface area [BSA] on the trunk, limbs and/or scalp, excluding psoriatic lesions on the face, genitals, and intertriginous areas, at Visit 1/Day 0.
Exclusion Criteria:
- Current diagnosis of unstable forms of psoriasis
- Other inflammatory skin disease in the treatment area
- Pigmentation, extensive scarring, pigmented lesions or sunburn in the treatment areas
- Planned exposure to natural or artificial sunlight
- Phototherapy and ultraviolet B radiation within 4 weeks prior to Visit 1/Baseline and during the trial;
- Current or past history of hypercalcemia, vitamin D toxicity, severe renal insufficiency, or severe hepatic disorders;
- Oral calcium supplements, vitamin D supplements, bisphosphonates or calcitonin within 4 weeks prior to Visit 1/Day 0 during the trial period.
- Planned initiation of, or changes to concomitant medication that could affect calcium metabolism during the trial;
- Planned initiation of, or changes to, concomitant estrogen therapy during the trial;
- Strong systemic cytochrome P450 3A4 (CYP 3A4) inhibitors within 4 weeks prior to Vist 1/Day 0 and during the trial period;
- Use of topical treatments, except for emollients and non-medicated shampoos, with a possible effect on psoriasis within 2 weeks prior to Visit 1/Day 0 and during the trial period;
- Systemic treatment with biological therapies
- Initiation of, or expected changes to, concomitant medication that may affect psoriasis during the trial period;
- Depression and endocrine disorders known to affect cortisol levels or HPA axis integrity, non-nocturnal sleep patterns
- Systemic medication that suppresses the immune system within 4 weeks prior to the Visit 1/Day 0 and during the trial period;
- Clinical signs of skin infection with bacteria, viruses, or fungi;
- Known human immunodeficiency virus [HIV] infection;
- Known or suspected of hypersensitivity to any component of the test product or reference product;
- Any chronic or acute medical condition that may pose a risk to the safety of the subject, or may interfere with the assessment of safety or efficacy in this trial;
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: MC2-01 Cream
MC2-01 cream (CAL and BDP, w/w 0.005%/ 0.064%).
|
MC2-01 (calcipotriene/betamethasone dipropionate, w/w 0.005%/0.064%)
|
Active Comparator: CAL/BDP combination
CAL/BDP ointment (w/w 0.005%/0.064%).
|
Calcipotriene/betamethasone (calcipotriene/ betamethasone dipropionate, w/w 0.005%/0.064%)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Maximum Plasma Concentration (Cmax) of the Active Ingredient Calcipotriene
Time Frame: Week 4
|
Geometric Mean for Maximum Plasma Concentration [Cmax] for the active ingredient Calcipotriene.
Plasma concentration was measured at the following timepoints: pre-dose, 30 min, 1, 2, 3, 5 and 7 hours post-dose
|
Week 4
|
Maximum Plasma Concentration (Cmax) of the Active Ingredient Calcipotriene
Time Frame: Week 8
|
Geometric Mean for Maximum Plasma Concentration [Cmax] for the active ingredient Calcipotriene.
Plasma concentration was measured at the following timepoints: pre-dose, 30 min, 1, 2, 3, 5 and 7 hours post-dose
|
Week 8
|
Maximum Plasma Concentration (Cmax) of Active Ingredient Betamethasone Dipropionate
Time Frame: Week 4
|
Geometric Mean for Maximum Plasma Concentration [Cmax] for the active ingredient Betamethasone Dipropionate.
Plasma concentration was measured at the following timepoints: pre-dose, 30 min, 1, 2, 3, 5 and 7 hours post-dose
|
Week 4
|
Maximum Plasma Concentration (Cmax) of Active Ingredient Betamethasone Dipropionate
Time Frame: Week 8
|
Geometric Mean for Maximum Plasma Concentration [Cmax] for the active ingredient Betamethasone Dipropionate.
Plasma concentration was measured at the following timepoints: pre-dose, 30 min, 1, 2, 3, 5 and 7 hours post-dose
|
Week 8
|
Maximum Plasma Concentration (Cmax) of the Metabolite MC1080
Time Frame: Week 4
|
Geometric Mean for Maximum Plasma Concentration [Cmax] for the metabolite MC1080.
Plasma concentration was measured at the following timepoints: pre-dose, 30 min, 1, 2, 3, 5 and 7 hours post-dose
|
Week 4
|
Maximum Plasma Concentration (Cmax) of the Metabolite MC1080
Time Frame: Week 8
|
Geometric Mean for Maximum Plasma Concentration [Cmax] for the metabolite MC1080.
Plasma concentration was measured at the following timepoints: pre-dose, 30 min, 1, 2, 3, 5 and 7 hours post-dose
|
Week 8
|
Maximum Plasma Concentration (Cmax) of Metabolite Betamethasone 17-propionate
Time Frame: Week 4
|
Geometric Mean for Maximum Plasma Concentration [Cmax] for the metabolite Betamethasone 17-propionate.
Plasma concentration was measured at the following timepoints: pre-dose, 30 min, 1, 2, 3, 5 and 7 hours post-dose
|
Week 4
|
Maximum Plasma Concentration (Cmax) of Metabolite Betamethasone 17-propionate
Time Frame: Week 8
|
Geometric Mean for Maximum Plasma Concentration [Cmax] for the metabolite Betamethasone 17-propionate.
Plasma concentration was measured at the following timepoints: pre-dose, 30 min, 1, 2, 3, 5 and 7 hours post-dose
|
Week 8
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Subjects With Hypothalamic-pituitary-adrenal [HPA] Suppression After 4 Weeks of Treatment
Time Frame: Week 4
|
The HPA axis evaluation is based on an Adrenocorticotropic hormone [ACTH] challenge test, defined by a 30 minutes ACTH stimulated cortisol value. Only subject with no HPA suppression at baseline were included in the analysis. The outcome measure lists the number of subjects with HPA suppression 30 minutes after ACTH challenge |
Week 4
|
Number of Subjects With Hypothalamic-pituitary-adrenal [HPA] Suppression After 8 Weeks of Treatment
Time Frame: Week 8
|
The HPA challenge test were only performed on subjects that were assigned to the MC2-01 cream group.
Out of a total of 32 subjects, 5 subjects were excluded from the analysis as they had HPA suppression at baseline
|
Week 8
|
Calcium Metabolism Evaluation in Albumin-corrected Serum Calcium
Time Frame: Baseline and week 4
|
Changes from baseline of albumin-corrected serum calcium [mmol/L]
|
Baseline and week 4
|
Calcium Metabolism Evaluation in Albumin-corrected Serum Calcium
Time Frame: Baseline and week 8
|
Changes from baseline in albumin-corrected serum calcium [mmol/L]
|
Baseline and week 8
|
Calcium Metabolism Evaluation of 24-hour Urinary Calcium Excretion
Time Frame: Baseline and week 4
|
Changes from baseline of 24-hour urinary calcium excretion [mmol/day]
|
Baseline and week 4
|
Calcium Metabolism Evaluation of 24-hour Urinary Calcium Excretion
Time Frame: Baseline and week 8
|
Changes from baseline of 24-hour urinary calcium excretion [mmol/day]
|
Baseline and week 8
|
Calcium Metabolism Evaluation of the Ratio of Urinary Calcium to Creatinine
Time Frame: Baseline and week 4
|
Changes from baseline in ratio of urinary calcium to creatinine defined as urinary calcium (mmol)/creatinine (g)
|
Baseline and week 4
|
Calcium Metabolism Evaluation of the Ratio of Urinary Calcium to Creatinine
Time Frame: Baseline and week 8
|
Changes from baseline in ratio of urinary calcium to creatinine defined as urinary calcium (mmol)/creatinine (g)
|
Baseline and week 8
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: George Han, Department of Dermatology, Mount Sinai Beth Israel
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
February 8, 2018
Primary Completion (Actual)
August 4, 2018
Study Completion (Actual)
August 4, 2018
Study Registration Dates
First Submitted
February 20, 2018
First Submitted That Met QC Criteria
March 6, 2018
First Posted (Actual)
March 13, 2018
Study Record Updates
Last Update Posted (Actual)
December 24, 2019
Last Update Submitted That Met QC Criteria
December 9, 2019
Last Verified
December 1, 2019
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- MC2-01-C3
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Psoriasis Vulgaris
-
LEO PharmaCompletedPlaque Psoriasis | Psoriasis VulgarisGermany
-
SoligenixRecruitingPsoriasis | Plaque Psoriasis | Psoriasis VulgarisUnited States
-
LEO PharmaTerminatedPsoriasis | Plaque Psoriasis | Psoriasis VulgarisBelgium, Germany, Italy, Spain, Denmark, Austria, France, Greece, Switzerland, United Kingdom, Netherlands, Sweden
-
PRCL Research Inc.CompletedPlaque Psoriasis | Psoriasis VulgarisCanada, Slovakia, Ukraine
-
Chinese University of Hong KongNot yet recruitingPsoriasis Vulgaris
-
University Hospital, GhentRecruitingPsoriasis VulgarisBelgium
-
University Hospital, GhentRecruitingPsoriasis VulgarisBelgium
-
University of California, San FranciscoNovartis Pharmaceuticals; National Psoriasis FoundationRecruitingPsoriasis VulgarisUnited States
-
University of California, San FranciscoSun Pharmaceutical Industries LimitedRecruiting
-
Centre for Human Drug Research, NetherlandsJanssen PharmaceuticalsRecruiting
Clinical Trials on MC2-01 Cream
-
MC2 TherapeuticsCompletedPhotoallergyUnited States
-
MC2 TherapeuticsCompletedPhototoxicityUnited States
-
MC2 TherapeuticsRecruitingEfficacy and Safety of MC2-25 Cream & Vehicle in Women With Vulvar Lichen Sclerosus (VLS) (Orchid 1)Vulvar Lichen SclerosusDenmark
-
MC2 TherapeuticsRecruitingChronic Kidney Disease-associated PruritusUnited Kingdom
-
MC2 TherapeuticsCompleted
-
MC2 TherapeuticsTerminatedPsoriasis VulgarisCzechia, Germany
-
MC2 TherapeuticsCompleted
-
Cassiopea SpACompletedAcne VulgarisUnited States, Bulgaria, Georgia, Poland, Romania, Serbia
-
aRigen Pharmaceuticals, Inc.UnknownHerpes Zoster | Postherpetic NeuralgiaUnited States
-
Cassiopea SpACompletedAcne VulgarisUnited States, Georgia, Ukraine